SG11202000881VA - Adjuvant therapy for use in prostate cancer treatment - Google Patents

Adjuvant therapy for use in prostate cancer treatment

Info

Publication number
SG11202000881VA
SG11202000881VA SG11202000881VA SG11202000881VA SG11202000881VA SG 11202000881V A SG11202000881V A SG 11202000881VA SG 11202000881V A SG11202000881V A SG 11202000881VA SG 11202000881V A SG11202000881V A SG 11202000881VA SG 11202000881V A SG11202000881V A SG 11202000881VA
Authority
SG
Singapore
Prior art keywords
prostate cancer
cancer treatment
adjuvant therapy
adjuvant
therapy
Prior art date
Application number
SG11202000881VA
Other languages
English (en)
Inventor
F M J Debruyne
Original Assignee
Fund Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fund Sa filed Critical Fund Sa
Publication of SG11202000881VA publication Critical patent/SG11202000881VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
SG11202000881VA 2017-08-01 2018-02-23 Adjuvant therapy for use in prostate cancer treatment SG11202000881VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17184320 2017-08-01
PCT/EP2018/054470 WO2019025031A1 (en) 2017-08-01 2018-02-23 ADJUVANT TREATMENT FOR USE IN THE TREATMENT OF PROSTATE CANCER

Publications (1)

Publication Number Publication Date
SG11202000881VA true SG11202000881VA (en) 2020-02-27

Family

ID=59520769

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000881VA SG11202000881VA (en) 2017-08-01 2018-02-23 Adjuvant therapy for use in prostate cancer treatment

Country Status (12)

Country Link
US (2) US11771705B2 (de)
EP (1) EP3661520B1 (de)
JP (2) JP2020530031A (de)
CN (1) CN111295192A (de)
BR (1) BR112020002094A2 (de)
CA (1) CA3071660A1 (de)
ES (1) ES2906380T3 (de)
MY (1) MY197942A (de)
PL (1) PL3661520T3 (de)
RU (1) RU2758386C2 (de)
SG (1) SG11202000881VA (de)
WO (1) WO2019025031A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
CA2503549C (en) * 2002-10-23 2012-07-10 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
EP1562976B1 (de) * 2002-11-08 2010-05-26 Pantarhei Bioscience B.V. Synthese von oestetrol aus von oestron abgeleiteten steroiden
JP2006525306A (ja) * 2003-04-30 2006-11-09 デビオファーム ソシエテ アノニム ゴナドトロピン・ホルモン放出ホルモンを使用する方法及び組成物
WO2005063276A1 (en) * 2003-12-23 2005-07-14 Debiopharm S.A. Methods and compositions using gonadotropin hormone releasing hormone
WO2009137078A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
JP2012077020A (ja) * 2010-09-30 2012-04-19 Mochida Pharmaceut Co Ltd ゲスターゲンとGnRHアンタゴニストとの組合せ医薬

Also Published As

Publication number Publication date
PL3661520T3 (pl) 2022-03-28
EP3661520A1 (de) 2020-06-10
RU2758386C2 (ru) 2021-10-28
EP3661520B1 (de) 2021-12-01
JP2023085303A (ja) 2023-06-20
BR112020002094A2 (pt) 2020-07-28
CA3071660A1 (en) 2019-02-07
US20200246354A1 (en) 2020-08-06
US11771705B2 (en) 2023-10-03
US20230405019A1 (en) 2023-12-21
CN111295192A (zh) 2020-06-16
WO2019025031A1 (en) 2019-02-07
MY197942A (en) 2023-07-25
RU2020108631A3 (de) 2021-09-02
RU2020108631A (ru) 2021-09-02
ES2906380T3 (es) 2022-04-18
JP2020530031A (ja) 2020-10-15

Similar Documents

Publication Publication Date Title
IL290149A (en) Combined treatment for cancer
HK1247129A1 (zh) 治療癌症的聯合療法
IL267795A (en) Combined treatment for cancer
IL255060A0 (en) Combined treatment for cancer
HK1251475A1 (zh) 用於癌症治療的聯合療法
IL282663A (en) BT1718 for use in cancer treatment
PT3609497T (pt) Niraparib, acetato de abiraterona e prednisona para o tratamento do cancro da próstata
PL3253208T3 (pl) Terapie kombinowane do zastosowania w leczeniu nowotworu piersi
IL275517A (en) Combined methods and treatment of cancer
IL280830A (en) Bracelets for use in cancer treatment methods
IL266993A (en) Combined therapy for cancer treatment
PL3258931T3 (pl) Zastosowanie kabazitakselu w leczeniu nowotworu złośliwego prostaty
IL281281A (en) Combined treatment for prostate cancer
IL269121A (en) Usl-311 for use in the treatment of cancer
SG11202000881VA (en) Adjuvant therapy for use in prostate cancer treatment
GB201704909D0 (en) Cancer therapy
IL253642A0 (en) Combined treatment for cancer
GB201711855D0 (en) Cancer therapy
GB2578008B (en) 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment
ZA202001435B (en) Abx196 for use in the treatment of bladder cancer
GB201612794D0 (en) Therapeutic use of diethanololeamide in prostate cancer treatment
EP3706752A4 (de) Kombinationstherapie für krebsbehandlung
GB201711250D0 (en) Cancer therapy
GB201710198D0 (en) Cancer therapy
GB201704474D0 (en) Combination therapy for treatment of cancer